PIM Kinase Inhibition Sensitizes Neuroblastoma to Doxorubicin

This research investigates PIM kinase inhibition as a strategy to overcome chemoresistance in high-risk neuroblastoma by targeting MRP1 drug efflux pumps. The approach aims to enhance doxorubicin efficacy in tumors that have developed resistance through upregulated efflux mechanisms, potentially improving outcomes in relapsed disease.